Akebia Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Akebia Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Akebia Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Akebia Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Akebia Therapeutics Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP4274575A1 | Application | Therapeutische verfahren mit veadamdustat | A61K31/4418; A61P7/06 | November 15, 2023 |
| IL305910A | Application | Oral dosage formulation of {[ 5-(3- (chlorophenyl)- 3-hydroxypyridine-2- carbonyl] amino} acetic acid | A61K31/16; A61K31/4418; A61K9/2009; A61K9/2013; A61K9/2054; A61K9/2059; A61K9/2866; A61P7/06; C07D213/81 | November 01, 2023 |
| AU2022229275A1 | Application | Modulation of drug-drug interactions of vadadustat | A61K31/195; A61K31/4418; A61K31/785; A61P13/12 | October 12, 2023 |
| IL305487A | Application | Modulation of drug-drug interactions of vadadustat | A61K31/195; A61K31/4418; A61K31/785; A61P13/12 | October 01, 2023 |
| US20230295110A1 | Application | Phd inhibitor compounds, compositions, and methods of use | A61P27/02; A61P29/00; A61P35/00; A61P7/06; A61P9/00; C07D213/81; C07D401/04; C07D401/14; C07D405/12; C07D405/14; C07D413/04; C07D417/04 | September 21, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer